SciVision Biotech Inc
TWSE:1786

Watchlist Manager
SciVision Biotech Inc Logo
SciVision Biotech Inc
TWSE:1786
Watchlist
Price: 90.4 TWD -1.74% Market Closed
Market Cap: 6.4B TWD
Have any thoughts about
SciVision Biotech Inc?
Write Note

SciVision Biotech Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

SciVision Biotech Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
SciVision Biotech Inc
TWSE:1786
Cash from Operating Activities
NT$250.7m
CAGR 3-Years
16%
CAGR 5-Years
12%
CAGR 10-Years
30%
M
Medtecs International Corporation Ltd
SGX:546
Cash from Operating Activities
-$1.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
V
Visco Vision Inc
TWSE:6782
Cash from Operating Activities
NT$353.1m
CAGR 3-Years
8%
CAGR 5-Years
12%
CAGR 10-Years
N/A
P
Pegavision Corp
TWSE:6491
Cash from Operating Activities
NT$1.5B
CAGR 3-Years
-6%
CAGR 5-Years
36%
CAGR 10-Years
N/A
OK Biotech Co Ltd
TWSE:4155
Cash from Operating Activities
NT$178.9m
CAGR 3-Years
164%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

SciVision Biotech Inc
Glance View

Market Cap
6.4B TWD
Industry
Health Care

SciVision Biotech, Inc. engages in the research, development, and production of hyaluronic acid medical products. The company is headquartered in Kaohsiung, Kaohsiung. The company went IPO on 2010-12-29. The firm primarily provides subcutaneous fillers for plastic surgery facial injection, joint cavity injections for orthopedics use, as well as hyaluronic acid raw materials, among others. The firm is also involved in deoxyribonucleic acid (DNA) identification, detection, sequencing and application, as well as the manufacturing of care products and foods. The firm operates its business in the Americas, Europe, Asia, Middle East and Africa.

Intrinsic Value
178.54 TWD
Undervaluation 49%
Intrinsic Value
Price

See Also

What is SciVision Biotech Inc's Cash from Operating Activities?
Cash from Operating Activities
250.7m TWD

Based on the financial report for Sep 30, 2024, SciVision Biotech Inc's Cash from Operating Activities amounts to 250.7m TWD.

What is SciVision Biotech Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
30%

Over the last year, the Cash from Operating Activities growth was 10%. The average annual Cash from Operating Activities growth rates for SciVision Biotech Inc have been 16% over the past three years , 12% over the past five years , and 30% over the past ten years .

Back to Top